# OnCo record paper-crizotinib-paediatric-alcl-imt-jco-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-crizotinib-paediatric-alcl-imt-jco-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-crizotinib-paediatric-alcl-imt-jco-2017" ;
  schema:name "Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study"@en ;
  schema:alternateName "Mossé 2017"@en, "ADVL0912"@en ;
  schema:description "Crizotinib produced responses in 83 to 90 per cent of children with relapsed ALK-positive anaplastic large cell lymphoma, most of them complete."@en ;
  schema:url <https://onco.cc/key-papers/paper-crizotinib-paediatric-alcl-imt-jco-2017/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2017.73.4830>, <https://pubmed.ncbi.nlm.nih.gov/28787259/>, <https://europepmc.org/article/MED/28787259> ;
  onco:tag "lymphoma-evidence-entities" ;
  schema:sameAs <https://doi.org/10.1200/JCO.2017.73.4830> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Mossé YP, Voss SD, Lim MS, et al." ;
  onco:cancers <https://onco.cc/cancers/alk-positive-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/inflammatory-myofibroblastic-tumour/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:drugs <https://onco.cc/drugs/crizotinib/> ;
  onco:trials <https://onco.cc/trials/advl0912-crizotinib/> .